A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2015
Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
Epistemonikos ID: 32ff9c57c23303eced4a8d8092b5422f7a0d3e12
First added on: Nov 24, 2021